Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Zimmer Biomet Holdings, Inc. securities (NYSE:ZBH) from September 7, 2016 through October 31, 2016, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Zimmer Biomet investors under the federal securities laws.

To join the Zimmer Biomet class action, go to http://rosenlegal.com/cases-1006.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the complaint, defendants throughout the Class Period made false and misleading statements and/or failed to disclose that: (1) supply chain problems led to a decrease in order fulfillment rates, most notably within Zimmer Biomet’s knee and hip portfolios; (2) as such, Zimmer Biomet would not achieve its revenues and profit forecast; and (3) as a result, defendants’ statements about Zimmer Biomet’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 31, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1006.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.